Filter, as far as we know, Dan has never paid a penny for any of his shares. He also has a nice chunk of shares in Oxilio, so even if we go bust, he's likely to have some future in NXP001
The only logical conclusions I can draw is that Mulder is either working on behalf of some disgruntled ex director who holds a grudge or for vultures who are intent on keeping the price trashed in the hope they can pick it for peanuts. He can't be shorting at these prices.
I sincerely hope whoever it is ends up bitterly disappointed...although it seems a long way off just now.
Not sure how relevant this is for NXP002 but it's an interesting article from December that suggests that Tranilast can be used in tumour treatment, not to fight the disease, but in combination with existing oncology drugs to improve their effectiveness.
I would imagine that will only happen upon some kind of big pharma collaboration announcement though...and don't seem to have had too many of them since the legendary (mythical?) Japanese talks.
If you were to shorten what you said to: "I'm sure DG is desperate to raise", then I might agree. They don't seem to be able to do anything to add value.
You only ever appear during high volume pump n dump periods & the only 'contributions' you ever make is to pour bile on fellow posters who have different opinions to your own.
I can't remember any post you've made that doesn't involve insulting someone.
So I take it you get very upset by people who don't agree with your short term position. Why else would you care?
This will be back to where it was very shortly unless we get a breakthrough on the BD front. Read the small print:
"The Company will now consider the design and execution of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of olaparib. Securing these data will enable commencement of discussions with multiple potential commercialisation partners."
We're always one step away from actually talking to someone...and they will probably need to raise more money to fund it.
Just more hot air for the traders to glide on. Nothing for investors
I'm beginning to suspect a delisting would suit some, once the current money has taken things as far as they can go. The IP could be searched up on the cheap and the plc shareholders would probably all be forced out.
There seems to no desire to turn things around here.
To be honest, I think we're approaching a point now where the only 'deal' we'll be likely to see is another mates-rates out-licensing to a small outfit run by acquaintances.
I'm not convinced they have ever had talks with any big pharma about 002 or 004. You're not telling me that 3 years on, no one outside of the old board has ever learned who the big Japanese partners are that they said they were supposed to be talking to. Why the big secret?